Angion's ANG-3777 Faces Third Failure In 2021, This Time Flunks Acute Kidney Injury Trial

Angion Biomedica Corp (NASDAQ:ANGN) and Vifor Pharma shared results from the Phase 2 GUARD trial of Angion's ANG-3777 in cardiac surgery patients with cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI).

The trial did not meet its primary endpoint of percentage increase in serum creatinine measured between 24 hours after the end of surgery through day 6.
There was no significant difference in the short-term endpoint between ANG-3777 and placebo (8.4% vs. 7.3%, p=0.77)
The secondary endpoint of MAKE90 indicated a potential benefit, with fewer patients in the ANG-3777 arm having a MAKE90 event compared to those in the placebo arm.
MAKE90 is a composite endpoint combining death, initiation of renal replacement therapy, or over 25% decline in Estimated Glomerular Filtration Rate (eGFR) present 90 days after the surgery.
Angion and Vifor Pharma will continue to review the data based on the signal demonstrated in the clinically relevant MAKE90 secondary endpoint.
Other secondary endpoints did not show a clinical benefit, including endpoints on MAKE30, the incidence of AKI through Day 6.
The companies already suffered a setback when ANG-3777 failed to beat placebo to improve eGFR, a measure of kidney function.
Related: Angion Stock Falls As Lead Product Candidate Flunks In COVID-19 Trial.
Price Action: ANGN shares fell 18.9% at $3.49 during after-hours trading on Wednesday.

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.